Australian Paediatric Surveillance Unit study of haemoglobinopathies in Australian children

Elizabeth Argent1, Phillip Emder, Paul Monagle

  • 1Sydney Children's Hospital, Randwick, Australia. elizabeth.argent@sesiahs.health.nsw.gov.au

Insights

A study found that haemoglobinopathies, including sickle cell disease and thalassaemia, occur in Australian children. Early diagnosis and enhanced screening are recommended due to increasing population diversity.

Area of Science:

  • Paediatric Haematology
  • Genetic Disorders
  • Public Health Surveillance

Background:

  • Haemoglobinopathies are inherited blood disorders affecting red blood cells.
  • Australia's diverse population presents unique challenges for identifying genetic conditions.
  • Existing screening programs may not fully capture the incidence of haemoglobinopathies.

Purpose of the Study:

  • To determine the incidence and types of haemoglobinopathies in Australian children.
  • To analyze the distribution of haemoglobinopathies across different ethnic groups.
  • To assess the timing and methods of diagnosis for these conditions in Australia.

Main Methods:

  • Utilized the Australian Paediatric Surveillance Unit for case reporting (2004-2006).
  • Collected data on children under 15 years with newly diagnosed haemoglobinopathies.
  • Excluded carrier states like thalassaemia minor; focused on diagnosed conditions.

Main Results:

  • Reported a national incidence of 0.74 per 100,000 children (<15 years).
  • Confirmed 59 cases, with sickle cell disease (35.6%) and Hb H disease (28.8%) being most common.
  • Identified significant gaps in parental awareness of carrier status and antenatal diagnosis rates (5.1%).

Conclusions:

  • A notable number of haemoglobinopathy cases occur in Australian children, including recent immigrants.
  • Current screening and testing programs require enhancement to address the evolving genetic landscape.
  • Increased awareness among healthcare providers and the public is crucial for early detection.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...